#1NATCO 15th February 2024 Natco Pharma Limited Regd. Off. 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.. Telangana, INDIA. Tel: +91 40 23547532, Fax: +91 40 23548243 CIN: L24230TG1981PLC003201, www.natcopharma.co.in Corporate Relationship Department M/s. BSE Ltd Dalal Street, For, Mumbai 400001 Scrip Code: 524816 Manager - Listing M/s. National Stock Exchange of India Ltd "Exchange Plaza", Bandra Kurla Complex Bandra East, Mumbai 400051 Scrip Code: NATCOPHARM Dear Sir/Madam, Sub: Q3 FY24 Investor Presentation Please find enclosed herewith the Investor Presentation for the Quarter and nine months ended December 31, 2023. Thanking you Yours faithfully For NATCO Pharma Limited CHEKURI VENKAT RAMESH Ch. Venkat Ramesh Company Secretary & Compliance Officer Encl: as above#2NATCO Natco Pharma Limited Earnings Presentation Q3FY24#3Disclaimer THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF NATCO PHARMA LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE "COMPANY"). The material that follows is a Presentation of general background information about the Company's activities as at the date of the Presentation or as otherwise indicated. It is information given in summary form and does not purport to be complete and it cannot be guaranteed that such information is true and accurate. This Presentation has been prepared by and is the sole responsibility of the Company. By accessing this Presentation, you are agreeing to be bound by the trading restrictions. It is for general information purposes only and should not be considered as a recommendation that any investor should subscribe / purchase the Company shares. This Presentation includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward- looking terminology, including the terms “believes", "estimates", "anticipates", "projects", "expects", "intends", "may", "will", "seeks" or "should" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, aims, objectives, goals, future events or intentions. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this Presentation and include statements regarding the Company's intentions, beliefs or current expectations concerning, amongst other things, its results or operations, financial condition, liquidity, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance including those relating to general business plans and strategy of the Company, its future outlook and growth prospects, and future developments in its businesses and its competitive and regulatory environment. No representation, warranty or undertaking, express or implied, is made or assurance given that such statements, views, projections or forecasts, if any, are correct or that the objectives of the Company will be achieved. There are some important factors that could cause material differences to Company's actual results. These include (i) our ability to successfully implement our strategy (ii) our growth and expansion plans (iii) changes in regulatory norms applicable to the Company (iv) technological changes (v) investment and business income (vi) cash flow projections etc. (vii) exposure to market as well as other risks. The Company, as such, makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information or opinions contained herein. The information contained in this Presentation, unless otherwise specified is only current as of the date of this Presentation. The Company assumes no responsibility to publicly amend, modify or revise any forward-looking statements based on any subsequent development, information or events, or otherwise. Unless otherwise stated in this Presentation, the information contained herein is based on management information and estimates. Any opinions expressed in this presentation are subject to change without notice. The presentation should not be construed as legal, tax, investment or other advice. None of the Company or any of its affiliates, advisers or representatives accepts any liability whatsoever for any loss howsoever arising from any information presented or contained in this presentation. The information contained in this presentation has not been independently verified. Furthermore, no person is authorized to give any information or make any representation which is not contained in, or is inconsistent with, this presentation. Any such extraneous or inconsistent information or representation, if given or made, should not be relied upon as having been authorized by or on behalf of the Company. Further, past performance is not necessarily indicative of future results. This document is just a Presentation for information purposes and private circulation only and is not intended to be a "prospectus" or "offer document" or a "private placement offer letter" (as defined or referred to, as the case may be, under the Companies Act, 2013). It is clarified that this Presentation is not intended to be a document offering for subscription or sale of any securities or inviting offers from the Indian public (including any section thereof) or from persons residing in any other jurisdiction including the United States for the subscription to or sale of any securities including the equity shares of the Company or any of its subsidiaries. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of the Company's securities may be offered or sold in the United States without registration under the U.S. Securities Act of 1933, as amended, except pursuant to an exemption from registration there from. This document has not been and will not be reviewed or approved by a regulatory authority in India or by any stock exchange in India. This presentation is confidential and this presentation or any part thereof should not be used or relied upon by any other party or for any other purpose and should not be copied, reproduced, recirculated, redistributed, published in any media, website or otherwise, in any form or manner, in part or as a whole, without the express consent in writing of the Company. Any unauthorized use, disclosure or public dissemination of information contained herein is prohibited. The distribution of this presentation in certain jurisdictions may be restricted by law. Accordingly, any persons in possession of the aforesaid should inform themselves about and observe any such restrictions. Natco Pharma Limited - Earnings Presentation - Q3FY24#4Table of Contents 1 Q3FY24 Key Business & Financial Highlights 2 Financial Summary 3 Product Portfolio & Pipeline Natco Pharma Limited - Earnings Presentation - Q3FY24#51 Q3FY24 Key Business & Financial Highlights Natco Pharma Limited - Earnings Presentation - Q3FY24#6Q3FY24 - Key Business & Financial Highlights Total Revenue stood at INR 7,956 mn | Pharma Export Formulations at INR 6,056 mn | Domestic Formulations at INR 994 mn | Agchem at INR 141 mn Earnings Before Interest Tax Depreciation and Amortization stood at INR 3,051 mn | EBITDA Margin for Q3FY24 was at 38.4% Net Profit for the quarter was at INR 2,127 mn Basic and Diluted EPS for the quarter is INR 11.88 per share Board has approved third interim dividend of INR 1.25 per equity share of INR 2/- for the year FY23-24 Investment of US$2mn in Cellogen Therapeutics Private Ltd., with R&D programs involving cell and gene therapy solutions *EBITDA and EBITDA Margin includes other income Natco Pharma Limited - Earnings Presentation - Q3FY24 5#7Q3FY24 - Quarterly Performance Revenue Breakup (INR Mn) Revenue Breakup (%) - Q3FY24 6% 4% 2% Revenue Division Q3FY24 Q3FY23 Q2FY24 12% A) API Revenue 463 426 778 B) Formulation 76% B1) Formulation - Exports (incl profit share, license income, export service income & Subsidiaries) ■ Export Formulation 6,056 3,337 7,923 ■Crop Health Science ■Domestic Formulation ■ API ■ Other operating and non-operating income B2) Formulation - Domestic 994 1,011 1,025 Formulations Total Revenue (B1 + B2) 7,050 4,348 8,948 Revenue Breakup (%) - 9MFY24 4% 6% 3% C) Crop Health Sciences 141 99 558 11% D) Other Operating & Non - operating incomes 302 260 324 Consolidated Total Revenue 7,956 5,133 10,608 Natco Pharma Limited - Earnings Presentation - Q3FY24 ■ Export Formulation ■Crop Health Science ■ Other operating and non-operating income 76% ■ Domestic Formulation ■ API#82 Financial Summary Natco Pharma Limited - Earnings Presentation - Q3FY24#9Consolidated Profit & Loss Statement Profit & Loss Statement (INR Million) Total Revenue Total Expenses (before finance cost and depreciation) Q3FY24 Q3FY23 Q2FY24 7,956 5,133 10,608 4,905 3,866 5,734 Earnings before interest, tax, depreciation and amortization (EBITDA) 3,051 1,267 4,874 EBITDA Margin* (%) 38.4% 24.7% 45.9% Finance cost Depreciation Profit before tax (PBT) Tax 46 38 42 442 415 436 2,563 814 4,396 436 191 706 Profit after tax (PAT) 2,127 623 3,690 PAT Margin (%) 26.7% 12.1% 34.8% Reported Earnings per share (EPS) INR Basic and Diluted 11.88 3.41 20.60 *includes other income Natco Pharma Limited - Earnings Presentation - Q3FY24 8#103 Key Product Pipeline Natco Pharma Limited - Earnings Presentation - Q3FY24#11Key Product Pipeline - USA 23 Para IVs in the pipeline >>> 15 Approved (either tentative or fully) Key Solo FTFs (Para IV) in the pipeline Key Para IV products in the pipeline Therapeutic Key Brand Molecule Key Brand Molecule Segment Primary Indication Tracleer Kyprolis Bosentan (32mg) Anti-hypertensive Eliquis Apixaban Therapeutic Segment Primary Indication Anticogulant Carfilzomib (10mg) Cancer/Multiple Myeloma Ozempic Semaglutide pen Diabetes Imbruvica Ibrutinib (tablet) Cancer/Leukaemia Zydelig Idelalisib Cancer Pomalyst Pomalidomide Lynparza Olaparib Ovarian/Breast Cancer Lonsurf Ozempic Semaglutide pen (8mg/3ml) Diabetes Trifluridine/Tipracil Yondelis Trabectedin Balversa Erdafitinib Bladder Cancer Wegovy Semaglutide Weight Loss Calquence Acalabrutinib Cancer/Multiple Myeloma Metastatic colorectal cancer Advanced soft-tissue sarcoma/ ovarian cancer Cancer/Blood Note: Data as of Dec 31, 2023 Natco Pharma Limited - Earnings Presentation - Q3FY24 10#12X in NATCO Thank You Contact: Rajeev Menon - Investor Relations Rajesh Chebiyam - EVP, Crop Health Sciences [email protected]/[email protected] 040-23546564 https://twitter.com/pharma natco https://www.linkedin.com/company/natcopharma